[Skip to Content]
[Skip to Content Landing]

Association of Metabolic Surgery With Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes and Obesity

Educational Objective
To understand the benefits of metabolic surgery for patients with type 2 diabetes and obesity.
1 Credit CME
Key Points

Question  Is there an association between metabolic surgery and major adverse cardiovascular events (all-cause mortality, coronary artery events, cerebrovascular events, heart failure, nephropathy, and atrial fibrillation) in patients with type 2 diabetes and obesity?

Findings  In this retrospective cohort study of 13 722 patients (including 2287 patients who underwent metabolic surgery and 11 435 matched controls), metabolic surgery was significantly associated with a lower risk of major adverse cardiovascular events (hazard ratio, 0.61).

Meaning  Among patients with type 2 diabetes and obesity, metabolic surgery was significantly associated with a lower risk of incident major adverse cardiovascular events.

Abstract

Importance  Although metabolic surgery (defined as procedures that influence metabolism by inducing weight loss and altering gastrointestinal physiology) significantly improves cardiometabolic risk factors, the effect on cardiovascular outcomes has been less well characterized.

Objective  To investigate the relationship between metabolic surgery and incident major adverse cardiovascular events (MACE) in patients with type 2 diabetes and obesity.

Design, Setting, and Participants  Of 287 438 adult patients with diabetes in the Cleveland Clinic Health System in the United States between 1998 and 2017, 2287 patients underwent metabolic surgery. In this retrospective cohort study, these patients were matched 1:5 to nonsurgical patients with diabetes and obesity (body mass index [BMI] ≥30), resulting in 11 435 control patients, with follow-up through December 2018.

Exposures  Metabolic gastrointestinal surgical procedures vs usual care for type 2 diabetes and obesity.

Main Outcomes and Measures  The primary outcome was the incidence of extended MACE (composite of 6 outcomes), defined as first occurrence of all-cause mortality, coronary artery events, cerebrovascular events, heart failure, nephropathy, and atrial fibrillation. Secondary end points included 3-component MACE (myocardial infarction, ischemic stroke, and mortality) and the 6 individual components of the primary end point.

Results  Among the 13 722 study participants, the distribution of baseline covariates was balanced between the surgical group and the nonsurgical group, including female sex (65.5% vs 64.2%), median age (52.5 vs 54.8 years), BMI (45.1 vs 42.6), and glycated hemoglobin level (7.1% vs 7.1%). The overall median follow-up duration was 3.9 years (interquartile range, 1.9-6.1 years). At the end of the study period, 385 patients in the surgical group and 3243 patients in the nonsurgical group experienced a primary end point (cumulative incidence at 8-years, 30.8% [95% CI, 27.6%-34.0%] in the surgical group and 47.7% [95% CI, 46.1%-49.2%] in the nonsurgical group [P < .001]; absolute 8-year risk difference [ARD], 16.9% [95% CI, 13.1%-20.4%]; adjusted hazard ratio [HR], 0.61 [95% CI, 0.55-0.69]). All 7 prespecified secondary outcomes showed statistically significant differences in favor of metabolic surgery, including mortality. All-cause mortality occurred in 112 patients in the metabolic surgery group and 1111 patients in the nonsurgical group (cumulative incidence at 8 years, 10.0% [95% CI, 7.8%-12.2%] and 17.8% [95% CI, 16.6%-19.0%]; ARD, 7.8% [95% CI, 5.1%-10.2%]; adjusted HR, 0.59 [95% CI, 0.48-0.72]).

Conclusions and Relevance  Among patients with type 2 diabetes and obesity, metabolic surgery, compared with nonsurgical management, was associated with a significantly lower risk of incident MACE. The findings from this observational study must be confirmed in randomized clinical trials.

Trial Registration  ClinicalTrials.gov Identifier: NCT03955952

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

Article Information

Corresponding Author: Steven E. Nissen, MD, Cleveland Clinic JB-20, 9500 Euclid Ave, Cleveland, OH 44195 (nissens@ccf.org).

Accepted for Publication: August 19, 2019.

Published Online: September 2, 2019. doi:10.1001/jama.2019.14231

Author Contributions: Dr Aminian and Mr Zajichek had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Aminian, Zajichek, Arterburn, Brethauer, Schauer, Nissen.

Acquisition, analysis, or interpretation of data: Aminian, Zajichek, Wolski, Schauer, Kattan, Nissen.

Drafting of the manuscript: Aminian, Nissen.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Aminian, Zajichek, Wolski, Nissen.

Obtained funding: Aminian.

Administrative, technical, or material support: Aminian, Zajichek, Wolski, Schauer, Nissen.

Supervision: Aminian, Arterburn, Kattan, Nissen.

Conflict of Interest Disclosures: Dr Aminian reported receiving grants from Medtronic. Dr Arterburn reported receiving grants from the National Institutes of Health (NIH) and the Patient-Centered Outcomes Research Institute and receiving nonfinancial support from International Federation for the Surgery of Obesity and Metabolic Disorders Latin America Chapter. Dr Brethauer reported receiving grants from Medtronic and GI Windows. Dr Schauer reported receiving grants from Medtronic, Ethicon, and Pacira and receiving personal fees from Medtronic, GI Dynamics, WL Gore and Associates, Becton Dickinson Surgical, and Global Academy for Medical Education. Dr Kattan reported receiving grants from Medtronic and Novo Nordisk. Dr Nissen reported receiving a grant from Medtronic for the current study and receiving research support from Amgen, AbbVie, AstraZeneca, Cerenis, Eli Lilly, Esperion Therapeutics, Novo-Nordisk, The Medicines Company, Orexigen, Pfizer, and Takeda and consulting for a number of pharmaceutical companies without financial compensation (all honoraria, consulting fees, or any other payments from any for-profit entity are paid directly to charity, so neither income nor any tax deduction is received). No other disclosures were reported.

Funding/Support: This study was partially funded by an unrestricted grant from Medtronic. Dr Arterburn was supported by National Institute of Diabetes and Digestive and Kidney Diseases grant R01-DK105960.

Role of the Funder/Sponsor: Medtronic had no role in the design and conduct of the study; collection, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and the decision to submit the manuscript for publication.

Meeting Presentation: Presented at the European Society of Cardiology (ESC) Congress 2019; September 2, 2019; Paris, France.

Additional Contributions: We acknowledge Alex Milinovich, BA, and Jian Jin, MS, from Department of Quantitative Health Sciences, Cleveland Clinic, for creation of the database. Mssrs Milinovich and Jin did not receive compensation for their role in the study.

References
1.
Ikramuddin  S, Korner  J, Lee  WJ,  et al.  Lifestyle intervention and medical management with vs without Roux-en-Y gastric bypass and control of hemoglobin A1c, LDL cholesterol, and systolic blood pressure at 5 years in the Diabetes Surgery Study.  JAMA. 2018;319(3):266-278. doi:10.1001/jama.2017.20813PubMedGoogle ScholarCrossref
2.
Mingrone  G, Panunzi  S, De Gaetano  A,  et al.  Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial.  Lancet. 2015;386(9997):964-973. doi:10.1016/S0140-6736(15)00075-6PubMedGoogle ScholarCrossref
3.
Schauer  PR, Bhatt  DL, Kirwan  JP,  et al; STAMPEDE Investigators.  Bariatric surgery versus intensive medical therapy for diabetes—5-year outcomes.  N Engl J Med. 2017;376(7):641-651. doi:10.1056/NEJMoa1600869PubMedGoogle ScholarCrossref
4.
Johnson  BL, Blackhurst  DW, Latham  BB,  et al.  Bariatric surgery is associated with a reduction in major macrovascular and microvascular complications in moderately to severely obese patients with type 2 diabetes mellitus.  J Am Coll Surg. 2013;216(4):545-556. doi:10.1016/j.jamcollsurg.2012.12.019PubMedGoogle ScholarCrossref
5.
Benotti  PN, Wood  GC, Carey  DJ,  et al.  Gastric bypass surgery produces a durable reduction in cardiovascular disease risk factors and reduces the long-term risks of congestive heart failure.  J Am Heart Assoc. 2017;6(5):e005126. doi:10.1161/JAHA.116.005126PubMedGoogle ScholarCrossref
6.
Sjöström  L, Peltonen  M, Jacobson  P,  et al.  Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications.  JAMA. 2014;311(22):2297-2304. doi:10.1001/jama.2014.5988PubMedGoogle ScholarCrossref
7.
Milinovich  A, Kattan  MW.  Extracting and utilizing electronic health data from Epic for research.  Ann Transl Med. 2018;6(3):42. doi:10.21037/atm.2018.01.13PubMedGoogle ScholarCrossref
8.
Kho  AN, Hayes  MG, Rasmussen-Torvik  L,  et al.  Use of diverse electronic medical record systems to identify genetic risk for type 2 diabetes within a genome-wide association study.  J Am Med Inform Assoc. 2012;19(2):212-218. doi:10.1136/amiajnl-2011-000439PubMedGoogle ScholarCrossref
9.
Grambsch  PM, Therneau  TM.  Proportional hazards tests and diagnostics based on weighted residuals.  Biometrika. 1994;81(3):515-526. doi:10.1093/biomet/81.3.515Google ScholarCrossref
10.
van Buuren  S, Groothuis-Oudshoorn  K.  mice: Multivariate Imputation by Chained Equations in R.  J Stat Softw. 2011;45(3):1-67. doi:10.18637/jss.v045.i03Google Scholar
11.
Frank E Harrell Jr. rms: Regression Modeling Strategies: R package version 5.1-2. Cran R website. https://cran.r-project.org/web/packages/rms/index.html. 2018. Accessed August 20, 2019.
12.
R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing website. https://www.R-project.org/. 2018. Accessed August 20, 2019.
13.
VanderWeele  TJ, Ding  P.  Sensitivity analysis in observational research: introducing the E-value.  Ann Intern Med. 2017;167(4):268-274. doi:10.7326/M16-2607PubMedGoogle ScholarCrossref
14.
Sabatine  MS, Giugliano  RP, Keech  AC,  et al; FOURIER Steering Committee and Investigators.  Evolocumab and clinical outcomes in patients with cardiovascular disease.  N Engl J Med. 2017;376(18):1713-1722. doi:10.1056/NEJMoa1615664PubMedGoogle ScholarCrossref
15.
Wing  RR, Bolin  P, Brancati  FL,  et al; Look AHEAD Research Group.  Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes.  N Engl J Med. 2013;369(2):145-154. doi:10.1056/NEJMoa1212914PubMedGoogle ScholarCrossref
16.
Douros  JD, Tong  J, D’Alessio  DA.  The effects of bariatric surgery on islet function, insulin secretion, & glucose control  [published online June 26, 2019].  Endocr Rev. doi:10.1210/er.2018-00183PubMedGoogle Scholar
17.
Batterham  RL, Cummings  DE.  Mechanisms of diabetes improvement following bariatric/metabolic surgery.  Diabetes Care. 2016;39(6):893-901. doi:10.2337/dc16-0145PubMedGoogle ScholarCrossref
18.
Chondronikola  M, Harris  LL, Klein  S.  Bariatric surgery and type 2 diabetes: are there weight loss-independent therapeutic effects of upper gastrointestinal bypass?  J Intern Med. 2016;280(5):476-486. doi:10.1111/joim.12527PubMedGoogle ScholarCrossref
19.
Fisher  DP, Johnson  E, Haneuse  S,  et al.  Association between bariatric surgery and macrovascular disease outcomes in patients with type 2 diabetes and severe obesity.  JAMA. 2018;320(15):1570-1582. doi:10.1001/jama.2018.14619PubMedGoogle ScholarCrossref
20.
Adams  TD, Gress  RE, Smith  SC,  et al.  Long-term mortality after gastric bypass surgery.  N Engl J Med. 2007;357(8):753-761. doi:10.1056/NEJMoa066603PubMedGoogle ScholarCrossref
21.
Jamaly  S, Carlsson  L, Peltonen  M, Jacobson  P, Karason  K.  Surgical obesity treatment and the risk of heart failure.  Eur Heart J. 2019;40(26):2131-2138. doi:10.1093/eurheartj/ehz295PubMedGoogle ScholarCrossref
22.
Sundström  J, Bruze  G, Ottosson  J, Marcus  C, Näslund  I, Neovius  M.  Weight loss and heart failure: a nationwide study of gastric bypass surgery versus intensive lifestyle treatment.  Circulation. 2017;135(17):1577-1585. doi:10.1161/CIRCULATIONAHA.116.025629PubMedGoogle ScholarCrossref
23.
Aggarwal  R, Harling  L, Efthimiou  E, Darzi  A, Athanasiou  T, Ashrafian  H.  The effects of bariatric surgery on cardiac structure and function: a systematic review of cardiac imaging outcomes.  Obes Surg. 2016;26(5):1030-1040. doi:10.1007/s11695-015-1866-5PubMedGoogle ScholarCrossref
24.
Alonso  A, Bahnson  JL, Gaussoin  SA,  et al; Look AHEAD Research Group.  Effect of an intensive lifestyle intervention on atrial fibrillation risk in individuals with type 2 diabetes: the Look AHEAD randomized trial.  Am Heart J. 2015;170(4):770-777.e5. doi:10.1016/j.ahj.2015.07.026PubMedGoogle ScholarCrossref
25.
Jones  NR, Taylor  KS, Taylor  CJ, Aveyard  P.  Weight change and the risk of incident atrial fibrillation: a systematic review and meta-analysis  [published online June 22, 2019].  Heart.doi:10.1136/heartjnl-2019-314931PubMedGoogle Scholar
26.
Jamaly  S, Carlsson  L, Peltonen  M, Jacobson  P, Sjöström  L, Karason  K.  Bariatric surgery and the risk of new-onset atrial fibrillation in Swedish obese subjects.  J Am Coll Cardiol. 2016;68(23):2497-2504. doi:10.1016/j.jacc.2016.09.940PubMedGoogle ScholarCrossref
27.
Young  L, Nor Hanipah  Z, Brethauer  SA, Schauer  PR, Aminian  A.  Long-term impact of bariatric surgery in diabetic nephropathy.  Surg Endosc. 2019;33(5):1654-1660. doi:10.1007/s00464-018-6458-8PubMedGoogle ScholarCrossref
28.
Imam  TH, Fischer  H, Jing  B,  et al.  Estimated GFR before and after bariatric surgery in CKD.  Am J Kidney Dis. 2017;69(3):380-388. doi:10.1053/j.ajkd.2016.09.020PubMedGoogle ScholarCrossref
29.
Carlsson  LMS, Sjöholm  K, Karlsson  C,  et al.  Long-term incidence of microvascular disease after bariatric surgery or usual care in patients with obesity, stratified by baseline glycaemic status: a post-hoc analysis of participants from the Swedish Obese Subjects study.  Lancet Diabetes Endocrinol. 2017;5(4):271-279. doi:10.1016/S2213-8587(17)30061-XPubMedGoogle ScholarCrossref
30.
O’Brien  R, Johnson  E, Haneuse  S,  et al.  Microvascular outcomes in patients with diabetes after bariatric surgery versus usual care: a matched cohort study.  Ann Intern Med. 2018;169(5):300-310. doi:10.7326/M17-2383PubMedGoogle ScholarCrossref
31.
Daigle  CR, Brethauer  SA, Tu  C,  et al.  Which postoperative complications matter most after bariatric surgery? prioritizing quality improvement efforts to improve national outcomes.  Surg Obes Relat Dis. 2018;14(5):652-657. doi:10.1016/j.soard.2018.01.008PubMedGoogle ScholarCrossref
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_LoginSubscribe_Purchase
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_LoginSubscribe_Purchase
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right

Name Your Search

Save Search
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase

Lookup An Activity

or

My Saved Searches

You currently have no searches saved.

With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Topics
State Requirements